Ann: Exopharm to Present at Key Exosome Industry Event, page-6

I recon the valuation here is about right. And think Pitt St is in lala land, by the way. The LEAP method seems to me to be an experimental (i.e., not validated) process to manufacture an experimental (i.e., not approved) medicine type.

So the question for me is "when do we expect to see proper revenue coming in?" And by that I mean on royalties etc. derived from the sale of the medicines (not nickel and dime up-fronts that just tick boxes).

The answer to me (a non expert) based on previous investments seems to be "quite a long way off".

So until that happens the >$2 price won't be a reality.

But what do I know? This is biotech where all laws of the universe are spaghettified. Actually, I hope I'm wrong